{"doi":"10.1093/infdis/jiae388","title":"Copy Number Variations of <i>Plasmodium vivax DBP1</i>, <i>EBP/DBP2</i>, and <i>RBP2b</i> in Ethiopians Who Are Duffy Positive and Duffy Negative","abstract":"Recent evidence challenges the belief that individuals who are Duffy-negative are resistant to Plasmodium vivax due to lacking the Duffy antigen receptor for chemokines. Erythrocyte-binding protein (EBP/DBP2) has shown moderate binding to Duffy-negative erythrocytes in vitro. Reticulocyte-binding protein 2b (RBP2b) interactions with transferrin receptor 1 suggest involvement in Duffy-negative infections. Gene copy number variations in PvDBP1, PvEBP/DBP2, and PvRBP2b were investigated in Duffy-positive and Duffy-negative P vivax infections from Ethiopia. Among Duffy-positive samples, 34% displayed PvDBP1 duplications (Cambodian type). In Duffy-negative infections, 30% showed duplications, mostly Cambodian type. For PvEBP/DBP2 and PvRBP2b, Duffy-positive samples exhibited higher duplication rates (1-8 copies for PvEBP/DBP2, 46%; 1-5 copies for PvRBP2b, 43%) as compared with Duffy-negative samples (20.8% and 26%, respectively). The range of copy number variations was lower in Duffy-negative infections. Demographic and clinical factors associated with gene multiplications in both Duffy types were explored, enhancing understanding of P vivax evolution in Africans who are Duffy negative.","journal":"The Journal of Infectious Diseases","year":2024,"id":477309,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9506,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":476980,"name":"Anthony Ford","orcid":"0000-0002-1615-2864","position":1,"is_corresponding":false},{"id":1165748,"name":"Rei Rama","orcid":null,"position":2,"is_corresponding":false},{"id":476982,"name":"Beka Raya Abagero","orcid":"0000-0002-7205-9496","position":3,"is_corresponding":false},{"id":476981,"name":"Daniel Kepple","orcid":"0000-0003-0566-3623","position":4,"is_corresponding":false},{"id":573718,"name":"Junya Tomida","orcid":"0000-0002-0813-5757","position":5,"is_corresponding":false},{"id":323747,"name":"Jean Popovici","orcid":"0000-0002-3135-1175","position":6,"is_corresponding":false},{"id":269981,"name":"Delenasaw Yewhalaw","orcid":"0000-0002-2907-9360","position":7,"is_corresponding":false},{"id":1149251,"name":"Eugenia Lo","orcid":"0000-0001-6794-4565","position":8,"is_corresponding":false},{"id":586879,"name":"Kareen Pestana","orcid":"0000-0001-9775-5378","position":0,"is_corresponding":true}],"reference_count":43,"raw_metadata":null,"created_at":"2026-07-19T02:06:33.741984Z","pmid":"39102894","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}